贝前列素联合纤溶酶治疗下肢动脉硬化闭塞症的临床观察

发布时间：2018-02-24 01:31

本文关键词： 贝前列素纤溶酶下肢动脉硬化闭塞症氧化应激血液流变学　出处：《中国药房》2017年29期 　论文类型：期刊论文

【摘要】：目的:观察贝前列素联合纤溶酶治疗下肢动脉硬化闭塞症(LEAOD)的临床疗效及安全性。方法:选择2015年1月-2016年1月于我院接受治疗的82例LEAOD患者,采用随机数字表法分为对照组和观察组,各41例。所有患者在原发疾病的治疗基础上均给予低盐、低脂饮食。对照组患者另给予纤溶酶注射液200单位,ivgtt,qd;观察组患者在对照组基础上加用贝前列素钠片40μg,tid,饭后服用。两组患者均治疗15 d。比较两组患者的临床疗效,治疗前后的血液流变学指标、踝肱指数、疼痛评分、冷感评分、间歇跛行评分和血清氧化应激指标,记录不良反应发生情况。结果:观察组患者的总有效率(90.24%)明显高于对照组(78.05%),差异有统计学意义(P0.05)。治疗前,两组患者上述指标比较,差异均无统计学意义(P0.05);治疗后,两组患者的全血高切黏度、血浆黏度、血细胞比容、纤维蛋白原含量、血小板黏附率、疼痛评分、冷感评分、间歇跛行评分和血清丙二醛水平均较治疗前明显降低,踝肱指数、血清超氧化物歧化酶水平、总抗氧化能力和血清谷胱甘肽过氧化物酶水平均较治疗前明显升高,且观察组各指标均明显优于对照组,差异均有统计学意义(P0.05)。两组患者不良反应发生率比较,差异无统计学意义(P0.05)。结论:贝前列素联合纤溶酶治疗LEAOD的疗效较好,能够有效缓解患者临床症状、促进其局部血液循环、改善其氧化应激水平,且安全性较高。
[Abstract]:Objective: to observe the clinical efficacy and safety of berprost combined with plasminase in the treatment of lower extremity arteriosclerosis obliterans (LEAODO). Methods: 82 patients with LEAOD received treatment from January 2015 to January 2016 in our hospital were selected. The patients were divided into control group (n = 41) and observation group (n = 41). All patients were treated with low salt on the basis of the treatment of primary diseases. Low fat diet. The patients in the control group were given another 200 units of plasminase injection iv GTT QD; the patients in the observation group were treated with 40 渭 g sodium berprost tablets after meals on the basis of the control group. The two groups were treated for 15 days. The clinical efficacy of the two groups was compared. Hemorheology index, ankle brachial index, pain score, cold feeling score, intermittent lameness score and serum oxidative stress index before and after treatment, Results: the total effective rate of patients in the observation group was significantly higher than that in the control group (P 0.05). The whole blood high shear viscosity, plasma viscosity, blood cell volume, fibrinogen content, platelet adhesion rate, pain score, cold feeling score, intermittent claudication score and serum malondialdehyde level were significantly lower than those before treatment, and ankle brachial index (malleolus index). The levels of serum superoxide dismutase (SOD), total antioxidant capacity and serum glutathione peroxidase (GSH) were significantly higher than those before treatment, and each index of the observation group was significantly better than that of the control group. There was no significant difference in the incidence of adverse reactions between the two groups (P 0.05). Conclusion: the efficacy of berprost combined with fibrinolytic enzyme in the treatment of LEAOD is better, which can effectively alleviate the clinical symptoms of patients and promote local blood circulation. The level of oxidative stress was improved and the safety was higher.
【作者单位】：郑州大学第五附属医院血管外科;
【基金】：河南省高等学校重点科研项目(No.16B320023)
【分类号】：R543.5

【相似文献】